These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35599598)

  • 41. Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season.
    Kawai AT; Li L; Kulldorff M; Vellozzi C; Weintraub E; Baxter R; Belongia EA; Daley MF; Jacobsen SJ; Naleway A; Nordin JD; Lee GM
    Pharmacoepidemiol Drug Saf; 2014 May; 23(5):548-53. PubMed ID: 24497128
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adverse events after Fluzone ® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013.
    Moro PL; Harrington T; Shimabukuro T; Cano M; Museru OI; Menschik D; Broder K
    Vaccine; 2013 Oct; 31(43):4984-7. PubMed ID: 23994022
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax(®)) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015.
    Moro PL; Winiecki S; Lewis P; Shimabukuro TT; Cano M
    Vaccine; 2015 Nov; 33(48):6684-8. PubMed ID: 26518405
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prediction of post-vaccination Guillain-Barré syndrome using data from a passive surveillance system.
    Luo C; Jiang Y; Du J; Tong J; Huang J; Lo Re V; Ellenberg SS; Poland GA; Tao C; Chen Y
    Pharmacoepidemiol Drug Saf; 2021 May; 30(5):602-609. PubMed ID: 33533072
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination - Five U.S. Mass Vaccination Sites, April 2021.
    Hause AM; Gee J; Johnson T; Jazwa A; Marquez P; Miller E; Su J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2021 May; 70(18):685-688. PubMed ID: 33956781
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adverse events reported following live, cold-adapted, intranasal influenza vaccine.
    Izurieta HS; Haber P; Wise RP; Iskander J; Pratt D; Mink C; Chang S; Braun MM; Ball R
    JAMA; 2005 Dec; 294(21):2720-5. PubMed ID: 16333007
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015.
    Miller ER; Lewis P; Shimabukuro TT; Su J; Moro P; Woo EJ; Jankosky C; Cano M
    Hum Vaccin Immunother; 2018; 14(8):1963-1969. PubMed ID: 29580194
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immediate hypersensitivity reactions following monovalent 2009 pandemic influenza A (H1N1) vaccines: reports to VAERS.
    Halsey NA; Griffioen M; Dreskin SC; Dekker CL; Wood R; Sharma D; Jones JF; LaRussa PS; Garner J; Berger M; Proveaux T; Vellozzi C; ; Broder K; Setse R; Pahud B; Hrncir D; Choi H; Sparks R; Williams SE; Engler RJ; Gidudu J; Baxter R; Klein N; Edwards K; Cano M; Kelso JM
    Vaccine; 2013 Dec; 31(51):6107-12. PubMed ID: 24120547
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety of COVID-19 Vaccination in United States Children Ages 5 to 11 Years.
    Hause AM; Shay DK; Klein NP; Abara WE; Baggs J; Cortese MM; Fireman B; Gee J; Glanz JM; Goddard K; Hanson KE; Hugueley B; Kenigsberg T; Kharbanda EO; Lewin B; Lewis N; Marquez P; Myers T; Naleway A; Nelson JC; Su JR; Thompson D; Olubajo B; Oster ME; Weintraub ES; Williams JTB; Yousaf AR; Zerbo O; Zhang B; Shimabukuro TT
    Pediatrics; 2022 Aug; 150(2):. PubMed ID: 35581698
    [TBL] [Abstract][Full Text] [Related]  

  • 50. COVID-19 Vaccine Safety in Children Aged 5-11 Years - United States, November 3-December 19, 2021.
    Hause AM; Baggs J; Marquez P; Myers TR; Gee J; Su JR; Zhang B; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(5152):1755-1760. PubMed ID: 34968370
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status - United States, January 12, 2022-March 28, 2022.
    Hause AM; Baggs J; Marquez P; Abara WE; Baumblatt JG; Thompson D; Su JR; Myers TR; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(28):899-903. PubMed ID: 35834416
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Age inappropriate influenza vaccination in infants less than 6 months old, 2010-2018.
    Suragh TA; Hibbs B; Marquez P; McNeil MM
    Vaccine; 2020 May; 38(21):3747-3751. PubMed ID: 32273185
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reports of cell-based influenza vaccine administered during pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2013-2020.
    Moro PL; Marquez P
    Vaccine; 2021 Jan; 39(4):678-681. PubMed ID: 33358703
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: Reports to the vaccine adverse event reporting system.
    Woo EJ; Moro PL
    Vaccine; 2021 Mar; 39(13):1812-1817. PubMed ID: 33678452
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database.
    Deb A; Abdelmalek J; Iwuji K; Nugent K
    J Prim Care Community Health; 2021; 12():21501327211029230. PubMed ID: 34219532
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.
    Varricchio F; Iskander J; Destefano F; Ball R; Pless R; Braun MM; Chen RT
    Pediatr Infect Dis J; 2004 Apr; 23(4):287-94. PubMed ID: 15071280
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative safety of two recombinant hepatitis B vaccines in children: data from the Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD).
    Niu MT; Rhodes P; Salive M; Lively T; Davis DM; Black S; Shinefield H; Chen RT; Ellenberg SS
    J Clin Epidemiol; 1998 Jun; 51(6):503-10. PubMed ID: 9635999
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reported rates of all-cause serious adverse events following immunization with BNT-162b in 5-17-year-old children in the United States.
    Mangat HS; Rippon B; Reddy NT; Syed AA; Maruthanal JM; Luedtke S; Puthumana JJ; Srivatsa A; Bosman A; Kostkova P
    PLoS One; 2023; 18(2):e0281993. PubMed ID: 36800368
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Making US poison centers a part of the solution to the COVID-19 pandemic.
    Spyker DA; Bronstein AC; Weber JA
    Clin Toxicol (Phila); 2022 Jan; 60(1):102-114. PubMed ID: 34448649
    [TBL] [Abstract][Full Text] [Related]  

  • 60. COVID-19 Vaccine Safety First Year Findings in Adolescents.
    Hesse EM; Hause A; Myers T; Su JR; Marquez P; Zhang B; Cortese MM; Thames-Allen A; Curtis CR; Maloney SA; Thompson D; Nair N; Alimchandani M; Niu M; Gee J; Shay DK; Shimabukuro TT;
    Pediatrics; 2023 May; 151(5):. PubMed ID: 37082919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.